- Conditions
- Sickle Cell Disease, Sickle Cell Anemia, Sickle Cell Disorders, Hemoglobin S Disease, Sickling Disorder Due to Hemoglobin S
- Interventions
- HQK-1001
- Drug
- Lead sponsor
- HemaQuest Pharmaceuticals Inc.
- Industry
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 9
- States / cities
- Oakland, California • Miami, Florida • Augusta, Georgia + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,697
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- LPL Deficiency
- Interventions
- alipogene tiparvovec, Prednisolone, Cyclosporins, Mycophenolate mofetil
- Drug
- Lead sponsor
- UniQure Biopharma B.V.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Down Syndrome (DS), Keratoconus, Pellucid Marginal Degeneration, Forme Fruste Keratoconus (FFK)
- Interventions
- Epi-ON corneal cross-linking (CXL)
- Combination Product
- Lead sponsor
- Woolfson Eye Institute
- Other
- Eligibility
- 8 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 12
- States / cities
- Atlanta, Georgia • Canton, Georgia • Cumming, Georgia + 8 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- NS-050/NCNP-03, Placebo
- Drug
- Lead sponsor
- NS Pharma, Inc.
- Industry
- Eligibility
- 4 Years to 15 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 3 more
- Conditions
- Retinitis Pigmentosa
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Interventions
- VX-407, Placebo, Midazolam
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS), Epidermal Nevus Syndrome
- Interventions
- Burosumab
- Drug
- Lead sponsor
- Laura Tosi
- Other
- Eligibility
- Not listed
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
- Interventions
- trivalent influenza vaccine, Immunoenzyme technique, Laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 459 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2013
- U.S. locations
- 2
- States / cities
- Duarte, California • Pasadena, California
- Conditions
- RAI1 Gene 17P11.2 Deletion+Duplication
- Interventions
- Electroencephalography/Polysomnography (EEG/PSG), Skin Biopsy, Blood draw
- Diagnostic Test · Procedure
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 1 Month to 80 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Down Syndrome, Cognitive Dysfunction
- Interventions
- Aricept (donepezil hydrochloride), Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 11 Years to 17 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 2
- States / cities
- San Antonio, Texas • Herndon, Virginia
- Conditions
- Tumors Characterized by Genetic Abnormalities of ALK
- Interventions
- LDK378
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Boston, Massachusetts • New York, New York + 3 more
- Conditions
- Huntington's Disease
- Interventions
- Not listed
- Lead sponsor
- University College, London
- Other
- Eligibility
- 11 Years to 75 Years
- Enrollment
- 2,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2017
- U.S. locations
- 6
- States / cities
- Englewood, Colorado • Washington D.C., District of Columbia • Baltimore, Maryland + 3 more
- Conditions
- Polycystic Kidney, Autosomal Dominant
- Interventions
- Tesevatinib
- Drug
- Lead sponsor
- Kadmon, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 62 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Denver, Colorado • Kansas City, Kansas + 8 more
- Conditions
- Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
- Interventions
- Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, Placebo (Study Part 2), ACI-24.060 at Dose A in Study Part 2, ACI-24.060 at Dose B in Study Part 2, ACI-24.060 at Dose C in Study Part 2, Placebo (Study Part 1b), ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b
- Biological
- Lead sponsor
- AC Immune SA
- Industry
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more
- Conditions
- Adult Spinal Deformity, Scoliosis, Kyphosis, Sagittal Imbalance
- Interventions
- Index or spine revision surgery for complex adult spinal deformity
- Procedure
- Lead sponsor
- International Spine Study Group Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2032
- U.S. locations
- 17
- States / cities
- La Jolla, California • Sacramento, California • San Francisco, California + 11 more
- Conditions
- Usher Syndrome, Cochlear Implantation
- Interventions
- Experimental manipulation of stimulation parameters
- Other
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 1 Year to 85 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Columbus, Ohio • Nashville, Tennessee
- Conditions
- Recurrent Basal Cell Carcinoma
- Interventions
- Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle
- Drug
- Lead sponsor
- Sol-Gel Technologies, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 14
- States / cities
- Apple Valley, California • Colton, California • Fremont, California + 11 more
- Conditions
- Patent Ductus Arteriosus
- Interventions
- feeding, fasting
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 23 Weeks to 33 Weeks
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 14
- States / cities
- San Francisco, California • San Jose, California • Chicago, Illinois + 11 more
- Conditions
- 22q11.2 Deletion Syndrome, Velo-Cardio-Facial Syndrome
- Interventions
- Cognitive remediation program, Small group social skills training
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 11 Years to 17 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Cytomegalovirus Infections, HIV Infections
- Interventions
- Zidovudine, Didanosine, Ganciclovir
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 3
- States / cities
- Irvine, California • Washington D.C., District of Columbia • Galveston, Texas
- Conditions
- Language Impairment, Down Syndrome
- Interventions
- Jasper-EMT with words and AAC
- Behavioral
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 30 Months to 54 Months
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Nashville, Tennessee
- Conditions
- Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
- Interventions
- autologous tumor cell vaccine, keyhole limpet hemocyanin, melphalan, sargramostim
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Timeline
- 1995 – 2007
- U.S. locations
- 3
- States / cities
- Little Rock, Arkansas • Bethesda, Maryland
- Conditions
- Congenital Hyperinsulinism
- Interventions
- RZ358 Sequential Group Cohort 1, RZ358 Sequential Group Cohort 2, RZ358 Sequential Group Cohort 3, RZ358 Sequential Group Cohort 4
- Drug
- Lead sponsor
- Rezolute
- Other
- Eligibility
- 2 Years to 45 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Fort Worth, Texas
- Conditions
- Facial Angiofibroma
- Interventions
- Rapamune
- Drug
- Lead sponsor
- Le Bonheur Children's Hospital
- Other
- Eligibility
- 3 Years to 45 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee